Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Pills in hand

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

Randomized trial questions superiority of insulin pumps over injections in children

Child with diabetes (symbolic image with model)

Insulin pumps and multiple daily injections deliver similar glycemic control and safety profiles when allocated alongside education and support at the point of type 1 diabetes diagnosis, say researchers.

Latest headlines

18-04-2019 | Risk factors | News

Study bolsters evidence for 5 alpha-reductase inhibitor link to type 2 diabetes

Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.

18-04-2019 | Mobile technology | News

Study highlights ‘immaturity’ of diabetes self-management apps

A large proportion of mobile apps for self-management of blood glucose do not provide real-time decision support for users with type 2 diabetes, researchers report.

17-04-2019 | Nephropathy | News

SONAR results support atrasentan for preserving renal function in type 2 diabetes

The endothelin receptor antagonist atrasentan may reduce the risk for kidney disease progression among certain high-risk patients with type 2 diabetes and kidney disease, indicate findings from the SONAR trial.

Features and expert interviews

19-02-2019 | Artificial pancreas systems | Feature | Article

What’s all the fuss about the DIY artificial pancreas?

DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.

14-12-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

16-11-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

image credits